Message #42 From:
NewsBot Date: November 28, 2005 02:00:00 AM
SWME News Swiss Medica Recognized as 2005 Company of the Year by Arthritis Foundation
TORONTO--(BUSINESS WIRE)--Nov. 28, 2005--Swiss Medica, Inc. (OTCBB:SWME) today announced that it has been awarded the Arthritis Foundation's (Northern California Chapter) prestigious 2005 Corporate Award. Grant Johnson, President and COO of Swiss Medica, along with Richard Weise, the inventor of O24, will be in attendance to accept the award on December 7, 2005, at the Annual Meeting of the Northern California Chapter of the Arthritis Foundation in San Francisco.
The award singles out Swiss Medica from a field of potential corporate candidates for the honor. Swiss Medica received this designation because it was determined that the Company has done more to assist the Foundation in its mission to advance its causes than any other contender.
In September 2005, Swiss Medica was Presenting Sponsor for the Arthritis Foundation's (Northern California Chapter) inaugural Arthritis Expo held in Santa Clara. Swiss Medica provided sponsorship funding, substantial product sampling, and on site participation by medical professionals.
The event provided an excellent opportunity to sample Swiss Medica's flagship product O24 Pain Neutralizer to a large segment of the Foundation's membership and physicians. Due in large part to the positive reaction to O24 Pain Neutralizer, product samples will be included in Northern California Chapter Arthritis Foundation member mailing being distributed in early 2006. O24 Pain Neutralizer is a medically and clinically tested product that has made a significant difference in the lives of many people living with the day to day challenges of pain associated with arthritis.
James R. Bouquin, President of the Northern California Chapter of the Arthritis Foundation says "Swiss Medica exemplifies the kind of corporate citizen that makes a real difference to the work of our organization and our members who are living with arthritis."
The Northern California Chapter of the Arthritis Foundation represents 2 million people in the Greater San Francisco Bay area managing Arthritis.
About Swiss Medica, Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.
Swiss Medica also manufactures PMS Escape(R) which holds US Patent #'s 5760014 and 5612320. PMS Escape(R) is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.
